Summary of COVID-19 Tenofovir studies
456 patient Tenofovir prophylaxis RCT: 66% fewer symptomatic cases (p=0.59) and 19% fewer cases (p=0.51).
Early terminated healthcare worker prophylaxis RCT in Spain, showing lower risk of symptomatic cases with both HCQ and tenofovir disoproxil fumarate/emtricitabine, without statistical significance due to the small number of events.
Aug 2022, Clinical Microbiology and Infection, https://www.sciencedirect.com/science/article/pii/S1198743X22003706, https://c19p.org/polotdftdf
2. Arruda et al., Clinical Features, Pathobiology, Efficacy, and Toxicity of Tenofovir Disoproxil Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections
84 patient Tenofovir early treatment RCT: 80% lower hospitalization (p=0.24) and 9% worse recovery (p=0.82).RCT 226 outpatients showing no significant difference with tenofovir disoproxil fumarate (TDF) alone or combined with emtricitabine (FTC) for mild to moderate COVID-19, compared with vitamin C.
Dec 2021, European J. Respiratory Medicine, https://europeanjournalofrespiratorymedicine.com/clinical-features-pathobiology-efficacy-and-toxicity-of-tenofovir-disoproxil-fumarate-and-emtricitabine-for-mild-to-moderate-sars-coV-2-infections, https://c19p.org/arrudatdf
3. Yazdan Pouri et al., Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial
60 patient Tenofovir late treatment RCT: 89% lower ventilation (p=0.11).RCT 60 hospitalized COVID-19 patients showing fewer mechanical ventilation and ICU days with tenofovir alafenamide fumarate (TAF) treatment in addition to remdesivir and corticosteroids.
Oct 2024, BMC Pharmacology and Toxicology, https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00781-3, https://c19p.org/yazdanpouritdf
4. Gaitán-Duarte et al., Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
321 patient Tenofovir late treatment RCT: 32% lower mortality (p=0.19).RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, 160 treated with emtricitabine + tenofovir, and 159 treated with the combination of both regimens. Statistically significant improvement was seen only for the combination of emtricitabine + tenofovir + rosuvastatin + colchicine.
Jul 2021, eClinicalMedicine, https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00523-X/fulltext, https://c19p.org/gaitanduartetdftdf
60 patient Tenofovir early treatment RCT: 11% improved recovery (p=0.47) and 37% improved viral clearance (p=0.1).
RCT 60 outpatients with mild/moderate COVID-19 showing no significant clinical benefit with tenofovir disoproxil fumarate plus emtricitabine. The primary endpoint of viral load reduction at day 4 was not met (p=0.13), though a secondary endpoint showed viral load reduction at day 7 (p=0.044). There was no significant difference in symptom recovery time between groups.
Aug 2021, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S258953702100273X, https://c19p.org/parientitdf
6. Montejano et al., Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
355 patient Tenofovir late treatment RCT: 76% higher mortality (p=0.38) and 6% lower progression (p=0.77).RCT 355 high-risk, mostly hospitalized COVID-19 patients showing no significant benefit with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment.
Aug 2022, Clinical Infectious Diseases, https://academic.oup.com/cid/article/76/3/e116/6652179, https://c19p.org/montejanotdf